Revolutionizing healthcare with real-world evidence

Kaolel is a California based company focused solely on the life science industry.

We are deeply embedded in real world evidence generation at all stages of development and commercialization of drugs and medical devices. Our core strength as an evidence-based platform is our unmatched solutions in characterizing real-world use, and clinical and economic value of medical products and devices.

We are a proven partner with solid knowledge in epidemiology methods, biostatistical analysis, data science and health economics. We work with our clients to lighten the burden of proof and communicate the real-world value of their medical product to meet the needs of their stakeholders.

We invite you to leverage our platform to accelerate product time to market, reduce development costs, and innovate with the power of real world data and artificial intelligence to stay ahead of the curve.

Meet the Team That Makes Kaolel

John Umejiego MD PhD

CEO/Founder

Connect on LinkedIn

Lakmini Bulathsinhala MPH

Vice President and Head of Evidence Generation

Connect on LinkedIn

Yangyang Deng PhD MS

Senior Biostatistician

Connect on LinkedIn

Gabriel Simpson

Business Development Specialist

Connect on LinkedIn

Kenechi Ezugwu R.Ph

Research Intern

Connect on LinkedIn

Kevin Cervantes MD

Senior Medical Scientist

Connect on LinkedIn

Who we partner & collaborate with

Kaolel offers a full range of real-world evidence services in strategy, consulting, study execution and technology that help deliver the best outcomes for patients. We work with stakeholders in Pharmaceutical, Biotechnology and medical device companies across the globe.

Research & Development

Research and Development (R&D) in the industry has traditionally relied on controlled, randomized clinical trials (RCTs) to gather evidence for the safety and efficacy of new interventions. While RCTs are the gold standard for establishing causality and ensuring that new drugs or interventions are safe and effective, they have limitations in terms of generalizability and capturing the complexity of real-world scenarios. Real World Evidence (RWE) offers a complementary approach by using data from real-world settings, such as:

Electronic health records
Insurance claims
Patient registries
And more

Medical Affairs

Medical Affairs is a strategic function within life science companies, responsible for the generation and communication of scientific and clinical data to a variety of stakeholders, including healthcare providers. With the increasing relevance of Real-World Evidence (RWE) in the healthcare ecosystem, Medical Affairs teams are poised to play an essential role in leveraging and communicating these insights. Here's how Kaolel can leverage RWE to support and drive the Medical Affairs evidence strategy.

Impactful Real-world evidence and HEOR solutions

Commercial and Market Access

Regulatory approval of new drug or medical device—that’s only half the battle. Getting the heath technology to the patient to improve health is the next hurdle. It involves navigating complex systems of health technology assessment (HTA), pricing, and reimbursement. Real-World Evidence (RWE) is becoming an increasingly influential tool in market access strategies. Here's how Kaolel can leverage RWE to support and drive your market access strategy.

RWE and HEOR Teams

Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) are integral parts of the life sciences industry. These teams focus on understanding the characteristics, value, effectiveness, and safety of treatments in real-world settings. Here's how Kaolel can leverage RWE to support and drive RWE and HEOR Teams strategy.

Impactful Real-World Evidence and HEOR Solutions